Acute Erythroblastic Leukemia

Search Trials
Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Mar 10, 2017
First Changed:
Jan 8, 2014
Disease(s):
Adult Acute Megakaryoblastic Leukemia (M7)
Intervention(s):
ixazomib
MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Dec 6, 2017
First Changed:
Jan 30, 2014
Disease(s):
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Intervention(s):
MEK inhibitor MEK162idarubicincytarabinepharmacological studylaboratory biomarker analysis
High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Status:
Completed
Last Changed:
Aug 9, 2010
First Changed:
Aug 9, 2010
Disease(s):
Accelerated Phase Chronic Myelogenous Leukemia
Intervention(s):
busulfancyclophosphamideallogeneic bone marrow transplantationmethylprednisolonemethotrexatecyclosporine
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
Status:
Completed
Last Changed:
Jun 4, 2013
First Changed:
Jan 27, 2003
Disease(s):
Adult Acute Basophilic Leukemia
Intervention(s):
cytarabinedaunorubicin hydrochlorideetoposidevalspodarfilgrastimbusulfanautologous hematopoietic stem cell transplantationperipheral blood stem cell transplantationaldesleukinclinical observationpharmacological study
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Status:
Terminated
Last Changed:
Jan 24, 2013
First Changed:
Nov 9, 2004
Disease(s):
Adult Acute Basophilic Leukemia
Intervention(s):
idarubicincytarabinebevacizumablaboratory biomarker analysis

Connect. Empower. Inspire.